Kirsten Drejer: “The time is right”

With big decisions on the horizon the time is right for a change of the guards at the helm of Danish biotech company Symphogen, says departing CEO Kirsten Drejer. From September 1st she will become an ordinary member of the board in the company she helped found in 2000 and has led since.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

MSD's Keytruda fejler i mavekræftstudie

Immunterapien Keytruda fra amerikanske Merck/MSD har ikke kunnet overgå kemoterapi i andenlinjebehandling af patienter med kræft i mave eller spiserør. Lægemidlet blev for få måneder siden godkendt i indikationen i tredje linje.

Latest Top picks in English

Related articles